Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

27 Jan 2014 14:00

RNS Number : 5936Y
ViaLogy PLC
27 January 2014
 



ViaLogy plc ("ViaLogy" or "the Company")

 

Result of General Meeting

 

ViaLogy is pleased to announce that at a General Meeting of the Company held earlier today, all resolutions were duly passed.

 

Further to the announcements of 7 January 2014 and 24 January 2014, ViaLogy has raised, via a Placing of 1,100,000,000 Ordinary Shares at 0.1p per share, £1.1 million (before expenses), and an additional £519,820 via an oversubscribed Open Offer to existing shareholders through the issue of 519,820,122 Ordinary Shares at 0.1p per share.

 

The Open Offer and Placing have therefore raised a total of £1,619,820 (before expenses). Application has been made for the admission of 1,649,820,122* Ordinary Shares of 0.1p each (following the Capital Reorganisation) to trading on AIM ("Admission") and dealings are expected to commence in these new shares on Tuesday 28 January 2014.

 

Following Admission, the Company shall have 2,689,460,366 ordinary shares of 0.1p in issue, which figure may be used after Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

Following their participation in the Placing and Open Offer, the following Directors of ViaLogy have an interest in the Ordinary Share Capital of the Company as follows:

 

Director

Current Holding

Placing Participation

Open Offer Entitlement

Total Holding

% Holding

Adam Reynolds

Nil

75,000,000

Nil

75,000,000

2.79

Dr. Robert Dean

2,897,304

Nil

1,448,652

4,345,956

0.17

Dr. Sandeep Gulati

6,904,412

Nil

3,912,184

10,816,596

0.41

Nicholas Mustoe

Nil

150,000,000

Nil

150,000,000

5.58

 

Capitalised terms used in this announcement are as defined in the shareholder circular dated 7 January 2014.

 

*includes 30,000,000 ordinary shares of 0.1peach being issued as part consideration for fees relating to Corporate Finance advice

 

For further information:

 

ViaLogy PLC

Mark Collingbourne mark.collingbourne@vialogy.com

 

Nominated Advisor to ViaLogy PLC (Cantor Fitzgerald Europe)

Mark Percy / Catherine Leftley - Corporate Finance +44 (0) 207 894 7000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMBXGDBUSDBGSR
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.